Company intelligence / Profile preview

Beyond Cancer

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Beyond Cancer has demonstrated preclinical efficacy of ultra-high-concentration nitric oxide therapy in murine models, showing tumor ablation and immune response activation. In humans, safety and immune response have been observed as monotherapy. A Phase 1b clinical trial combining LV UNO with anti-PD‑1 therapy is set to begin patient screening in early 2025. Preclinical data show enhanced survival when combined with checkpoint inhibitors compared to checkpoint inhibitor alone.

Therapeutic areas: Oncology
Modalities: Nitric oxide therapy (Ultra-high concentration nitric oxide, UNO)Small molecule drug (nitric oxide is a small gaseous molecule)
Industry: Biotech

Drug pipeline

2 assets

UNO

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

No major pharmaceutical partnerships disclosed as of June 2025.Collaboration implied with Israeli clinical sites for ongoing trials.

Beyond the preview

Go deeper on Beyond Cancer.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beyond Cancer.

Explore the full profile